Interview with Dominique Demolle , Co-founder & CEO, Aepodia
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Address: Avenue Albert Einstein 2A
1348 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 39 20 11
Web: http://http/www.aepodia.com
Aepodia S.A. (spin-off of a top 10 US Pharma Company) was created in March 2007 by a group of experts in early-phase clinical development. Since then, our company has grown and built a strong and a worldwide reputation in the early clinical drug development sector. We have established solid and effective collaborations with world pharmaceutical leaders, as well as with small biotech companies. The management and staff members have a background in pharmaceutical development that allows us to understand sponsor requirements and challenges and to meet their needs in an optimal way.
Our headquarters are located in Louvain-La-Neuve, Belgium, with offices in Paris-La Défense, France. Thanks to our strategic location in the center of Europe, we can cover the European phase I units. We also support clinical trials in the United-States and Singapore and provide easy access to patients.
Aepodia is a CRO sponsor representative providing customized services in Phase I/II clinical trials and in clinical development of Medical devices.
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA…
To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment.…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed…
The European Brain Council (EBC) is a key player in advancing brain health research and policy across Europe, bringing together diverse voices to address the pressing issues of neurological and…
James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe. In…
Last year the European Commission (EC) came out with a proposal to reform the EU’s core pharmaceutical legislation, aiming to address affordability, accessibility, and availability, among other objectives. One of…
Vikas Krishan, chief digital business officer at the global data and digital engineering solutions firm Altimetrik, outlines the implications of the European Union’s forthcoming AI Act for the pharma industry…
As the EU’s push to harmonise clinical assessments across its 27 member states moves from the initial Health Technology Assessment (HTA) regulation in 2022 to the European Joint Clinical Assessment…
Writing in DIA’s Global Forum magazine for June 2024, the organization’s Vedran Raguz reviews some of the key takeaways from DIA Europe 2024, namely the need for increased collaboration, alignment…
Founded in 1996 to coordinate and promote HIV vaccine development, IAVI has had a major impact across HIV vaccine development efforts, capacity building in low- and middle-income countries, advocacy work,…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
See our Cookie Privacy Policy Here
